Belvedere Trading
CRDF icon

Belvedere Trading’s Cardiff Oncology CRDF Stock Holding History

Belvedere Trading’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,800
Closed -$17.9K – 1024
2022
Q4 		$17.9K Buy
+12,800
New +$18.3K ﹤0.01% 841
2021
Q2 		– Sell
-13,000
Closed -$120K – 361
2021
Q1 		$120K Sell
13,000
-5,000
-28% -$60.7K 0.01% 199
2020
Q4 		$324K Buy
+18,000
New +$316K 0.01% 106

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Belvedere Trading's CRDF Position: Q1 2023 in Review

Belvedere Trading sold out of Cardiff Oncology (CRDF) in Q1 2023, closing a stake of 10,337 shares — an estimated $14.5K sold.

Belvedere Trading first reported a position in CRDF in Q3 2021 and held it in 2 quarters. The position peaked at $14.5K in Q4 2022. 55 funds tracked by Wall St. Rank hold CRDF as of Q1 2023.

  • Belvedere Trading reported no remaining Cardiff Oncology position as of Q1 2023 after selling out during the quarter.
  • Belvedere Trading sold 10,337 Cardiff Oncology shares in Q1 2023, an estimated $14.5K.
  • Belvedere Trading first reported a position in Cardiff Oncology in Q3 2021 and held it in 2 quarters.
  • Belvedere Trading's Cardiff Oncology position peaked at $14.5K in Q4 2022.
  • 55 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.